US Supreme Court to hear 'skinny label' patent fight involving Amarin

Core Viewpoint - The U.S. Supreme Court's decision to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa may significantly impact generic drug manufacturers and the "skinny label" strategy [1] Group 1: Patent Dispute - The case centers around Amarin Pharma's Vascepa, which is a cardiovascular drug [1] - The outcome of this dispute could set a precedent affecting the generic drug market [1] Group 2: Implications for Generic Drug Makers - The ruling may influence how generic drug makers approach the development and marketing of their products [1] - The "skinny label" strategy, which allows generics to avoid patent infringement by omitting certain indications, could be affected by the court's decision [1]